Document:

Exhibit 10.26

 EXHIBIT 10.26 
  
 March 3, 2004 
  
 Jane S. Doe 
 1 Somewhere Street 
  
 Richmond, VA
23060 
  
 Dear Jane : 
  
 I am pleased to announce that pursuant to the terms and conditions of the company’s
2000 Stock Incentive Plan (the ‘Plan’), you have been granted a Restricted Stock Award for 10,000 shares (the ‘Option’) of stock as outlined below. 
  
 Subject to the terms and conditions in the Plan, as amended from time to time and Exhibit A, attached hereto and made a part hereof
(together with this letter, the “Agreement”), your award is as follows: 
  

					
	Grant Date:	 	 February 9, 2004
	  	 
	Options Granted:	 	 10,000
	  	 
	Expiration Date:	 	 2/9/2011
	  	 
	Vesting Schedule:	 	 25% per year for 4 years
	  	 10% Earnings Growth Contingency

			
	 	 	 2,500 on 02/09/2005
	  	 2005 vs. 2004 or 2004 vs. 2003

	 	 	 2,500 on 02/09/2006
	  	 2006 vs. 2005 or 2005 vs. 2004

	 	 	 2,500 on 02/09/2007
	  	 2007 vs. 2006 or 2006 vs. 2005

	 	 	 2,500 on 02/09/2008
	  	 2008 vs. 2007 or 2007 vs. 2006

  
 Please indicate your
acceptance by executing two (2) original copies of theis Agreement and returning one (1) coy by U.S. Mail to Gwynn Noble. 
  

	
	 Very truly yours,

	
	 Martin L. Vaughan, II,

	 Chairman and Chief Executive Officer

  
 By my signature below, I hereby
acknowledge my Consent to Electronic Delivery, receipt of this Option, pursuant to all terms and conditions of the Plan, and electronic receipt of the Plan and Prospectus. I agree to conform to all of the terms and conditions of the Option and the
Plan. 
  

									
	 Signature:
	 	  

	 	 	 	 Date:
	 	  

	 	 	 Jane S. Doe
	 	 	 	 	 	 

  
 Note: If there are any
discrepancies in the name or address shown above, please make the appropriate corrections on this form. 

 EXHIBIT A 
  
 TERMS AND CONDITIONS 
 RESTRICTED STOCK AGREEMENT 
 FOR EXECUTIVE GROUP 
  
 1. Time and Operational Vesting of Restricted Stock. Except as
provided in these Terms and Conditions, the Restricted Stock shall vest and become nonforfeitable in accordance with the Vesting Schedule for each full year, up to a total of five (5) full years that the Employee continues to be employed by the
Company after the date of this Agreement, with the first vesting date being for 25% of the grant two (2) years after the date of grant and an additional 25% each year thereafter, subject to an additional qualification based on Company’s
operations described below. The period from the date hereof until the shares of Restricted Stock would have become 100% vested if time were the only criterion shall be referred to as the “Restricted Period.” 
  
 This award of Restricted Stock to Employee is intended to encourage Employee to cause the
operating earnings of Company to grow by at least 10% per calendar year. At each of the vesting dates set forth in the Vesting Schedule, Restricted Stock will be eligible to vest only if the Employee continues to be employed by the Company and the
Company achieves a 10% annual growth in fully diluted earnings per share based on Operating Income in at least one of the two preceding calendar years. If the earnings growth requirement has not been met at any of the vesting dates, all of the
Restricted Shares eligible for vesting on that date shall be cancelled. 
  
 2. Issuance of Certificates. The stock certificate(s) evidencing the Restricted Stock shall be issued and registered on the Company’s books and records in the name of the Employee as soon as practicable following the date
of this Agreement. The Company shall retain control of each award representing the Restricted Stock until such time as the Restricted Stock becomes vested in accordance with the terms herein. Company is granted a power of attorney, coupled with an
interest, to administer these shares in accordance with the terms of this award and the Plan. 
  
 Upon the written request of the Employee following the vesting of any portion of the shares of Restricted Stock prior to any event of forfeiture
hereunder, the Company will cause a stock certificate to be issued, without such restrictive legend, with respect to the vested portion of the shares of the Restricted Stock registered on the Company’s books and records in the name of the
Employee. Following the expiration of the Restricted Period, the Company will cause a stock certificate to be issued for any shares of Restricted Stock that have vested prior to any event of forfeiture hereunder and have not been reissued without
the restrictions described above. 
  
 3. Transferability.
During the Restricted Period, the Employee shall not sell, assign, transfer, pledge, exchange, hypothecate, or otherwise dispose of unvested Restricted Stock. Upon receipt by the Employee of stock certificate(s) representing vested shares without a
restrictive legend pursuant to the Agreement, the Employee may hold or dispose of the shares represented by such certificate(s), subject to compliance with (i) the terms and conditions of the Plan and this Agreement and (ii) applicable securities
laws of the United States of America and the Commonwealth of Virginia. 
  
 4. Shareholder Rights. Prior to any forfeiture of the shares of Restricted Stock and while the shares are Restricted Stock, the Employee shall, subject to the terms of this Agreement and the restrictions of the Plan, have all rights
of a shareholder with respect to the shares of Restricted Stock awarded hereunder, including the right to receive dividends and other distributions as and when declared by the Board of Directors of the Company and the right to vote the shares of
Restricted Stock. 
  
 5. Tax Withholding. The Company shall
have the right to retain and withhold from any award of the Restricted Stock, the amount of taxes required by any government to be withheld or otherwise deducted and paid with respect to such award. At its discretion, the Company may require the
Employee receiving shares of Restricted Stock to pay or otherwise reimburse the Company in cash for any such taxes required to be withheld by the Company and withhold any distribution in whole or in part until the Company is so paid or reimbursed.
In lieu thereof, the Company shall have the unrestricted right to withhold, from any other cash amounts due (or to become due) from the Company to the Employee, an amount equal to such taxes required to be withheld by the Company to reimburse the
Company for any 

 such taxes (or retain and withhold a number of shares of vested Restricted Stock, having a market value not less than the
amount of such taxes, and cancel in whole or in part any such shares so withheld, in order to reimburse the Company for any such taxes). 
  
 6. Death; Disability; Retirement; Termination of Employment. The shares of Restricted Stock not yet vested shall become 100% vested and
transferable in the event that the Employee dies or becomes Disabled while employed by the Company or an Affiliate during the Restricted Period. Upon attaining age 62 with 10 consecutive years of service with the Company or an Affiliate, or in any
other circumstance approved by the Committee in its sole discretion, the shares of Restricted Stock shall become 100% vested and transferable. In all events other than those previously addressed in this paragraph, if the Employee ceases to be an
employee of the Company or an Affiliate, the Employee shall be vested only as to that percentage of shares of Restricted Stock which are vested at the time of the termination of his employment and the Employee shall forfeit the right to the shares
of Restricted Stock which are not yet vested on the termination date. 
  
 7. No Right to Continued Employment. This Agreement does not confer upon the Employee any right with respect to continuance of employment by the Company or an Affiliate, nor shall it interfere in any way with the right of the Company
or an Affiliate to terminate his or her employment at any time. 
  
 8. Change of Control or Capital Structure. Subject to any required action by the shareholders of the Company, the number of shares of Restricted Stock covered by this award shall be proportionately adjusted and the terms of the
restrictions on such shares shall be adjusted as the Committee shall determine to be equitably required for any increase or decrease in the number of issued and outstanding shares of Common Stock of the Company resulting from any stock dividend (but
only on the Common Stock), stock split, subdivision, combination, reclassification, recapitalization or general issuance to the holders of Common Stock of rights to purchase Common Stock at substantially below its then fair market value or any
change in the number of shares of Common Stock outstanding effected without receipt of cash, property, labor or services by the Company or for any spin-off or other distribution of assets to shareholders. 
  
 In the event of a Change of Control, this award of Restricted Stock shall
immediately vest pursuant to the provisions of Section XIII(3) of the Plan. In the event of a change in the Common Stock of the Company as presently constituted, which is limited to a change of all or part of its authorized shares without par value
into the same number of shares with a par value, or any subsequent change into the same number of shares with a different par value, the shares resulting from any such change shall be deemed to be the Common Stock within the meaning of the Plan.

  
 The award of Restricted Stock pursuant to the Plan shall not
affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure or to merge or to consolidate or to dissolve, liquidate, sell or transfer all or any part of
its business or assets. 
  
 9. Governing Law. This
Agreement shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Virginia, except to the extent that federal law shall be deemed to apply. 
  
 10. Conflicts. In the event of any conflict between the provisions of the Plan as in effect on the date hereof and
the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof. 
  
 11. Employee Bound by Plan. The Employee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by
all the terms and provisions thereof. 
  
 12. Binding
Effect. Subject to the limitations stated herein and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of the Employee and the successors of the Company.

  
 13. Forfeiture of Certain Gains. 
  
 (a) Termination for Cause. If Employee’s employment is
terminated for “Cause” within one year of any vesting of Restricted Stock herein, the Employee shall pay to the Company an amount equal to the Fair Market Value of such Restricted Stock on the date of vesting without regard to any
subsequent market price increase or decrease. For purposes of this paragraph, “Cause” shall have the meaning ascribed to it in any employment agreement between the Employee and the Company that is in effect at the time of termination and,
if no such agreement exists, it shall mean: 

 (i) the willful and continued failure of the Employee to perform substantially the Employee’s
duties with the Company or one of its affiliates (other than any such failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to the Employee by the Company which
specifically identifies the manner in which the Company believes that the Employee has not substantially performed the Employee’s duties, or 
  
 (ii) the willful engaging by the Employee in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company.

  
 (b) Forfeiture if Employee Engages in Certain
Activities. If Employee engages in any activity in competition with any activity of the Company, or inimical, contrary or harmful to the interests of the Company, including but not limited to (i) accepting employment with or serving as a
consultant advisor or in any other capacity to an employer that is in competition with or acting against the interests of the Company, (ii) disclosing or misusing any confidential information or material concerning the Company or (iii) participating
in any hostile takeover attempt, then (1) any unvested Restricted Stock shall be forfeited and cancelled and (2) the Employee shall pay to the Company an amount equal to the Fair Market Value on the date of vesting, without regard to any subsequent
market price increase or decrease, of any Restricted Stock that vested within one year of the date such activity began. 
  
 (c) Right of Set-off. Employee hereby consents to a deduction from any amounts owed by the Company to Employee from time to time (including amounts
owed as wages or other compensation, fringe benefits or vacation pay, to the extent of any amounts Employee owes the Company under paragraph 13(a) and (b). Whether or not the Company elects to make any set-off in whole or in part, if Company does
not recover by means of set-off the full amount owed by Employee under paragraphs 13(a) and (b), Employee agrees to immediately pay the unpaid balance to the Company. 
  
 14. Notice and Consent to Electronic Delivery. The Company expects to deliver notices and certain documents
relating to its employee benefit plans by posting the information on the Company’s web site, intranet or electronic bulletin board or transmitting the material to employees by e-mail. These documents include employee benefits plans and any
amendments thereto, election forms, prospectuses, supplements to prospectuses, annual reports to shareholders, informational brochures and similar information. The Company will provide you with e-mail notification of the posting of any of the
foregoing documents. This method of notification and access to documents relating to employee benefit plans will be in lieu of paper delivery of the same documents. To satisfy legal requirements, your signature is an affirmative election to accept
electronic notification and delivery of these documents in lieu of paper delivery, as well as all other terms of the award. 
  
 15. Defined Terms. All terms used herein that are defined in the Plan shall have the meanings given to them in the Plan. 

 RESTRICTED STOCK AWARDS 
 FOR NAMED EXECUTIVE OFFICERS 
  

					
	 	  	AWARD DATE

	  	SHARES AWARDED

	 Daniel J. Donovan
	  	—  	  	—  
			
	 Thomas A. Golub
	  	—  	  	—  
			
	 Timothy J. Korman
	  	2/9/04	  	4,000
			
	 Robert B. Lockhart
	  	2/9/04	  	6,000
			
	 John P. McGrath
	  	2/9/04	  	2,500
			
	 Andrew L. Rogal
	  	—  	  	—  
			
	 Martin L. Vaughan, III
	  	2/9/04	  	6,000Agreement dated April 12, 2001

 Exhibit 10.1 
  
 AGREEMENT FOR RESEARCH FUNDING BY WAY OF CONTRIBUTION 
  
 TO THE EXPENSES SUSTAINED FOR RESEARCH PROJECTS AND 
  
 PROFESSIONAL TRAINING FALLING UNDER NATIONAL PROGRAMMES 
  
 TO BE DRAWN FROM 
  
 THE SPECIAL FUND FOR APPLIED RESEARCH 
  
 —*— 
  
 PRIVATE AGREEMENT 
  
 By private agreement, made in four originals to be deemed equally valid and binding 
  
 BY AND BETWEEN 
  

	•	Mr. Giuseppe Colona, born in Rome on 7/8/1942, with an address for service in his official capacity at Viale dell’Arte 25, Rome, acting in his capacity as an Executive Officer
representing “SANPAOLO IMI S.p.A” - a bank entered at no. 5084.9.0 in the Roll of Banks (Albo delle Banche) and parent company of the SANPAOLO IMI Group, entered at no. 1025.6, in the Roll of Banking Groups (Albo dei
Gruppi Bancari), member of the Italian Interbank Deposit Protection Fund (Fondo Interbancario di Tutela dei Depositi), with registered offices in Turin at Piazza San Carlo 156, as well as secondary, fixed representative offices in Rome at
Viale dell’Arte 25, fully paid-up share capital of 3,931,250,954.40 euro, Tax and Turin Companies Registry no. 06210280019 - by virtue of powers of attorney for the stipulation of deeds and agreements, notarised on 3 October 2000 by
Notary Daniele Bazzoni of Turin under file no. 79019, conferred on him by the Managing Director and legal representative of the aforesaid company, Dr. Rainer Stefano Masero, born in Como on 6 May 1944, company executive, with an address for service
in such official capacity in Turin at the aforementioned address, empowered for such purpose under the company’s current Articles of association as well as the resolution passed by the said company’s Board of Directors on 27 July 1999 and
filed with the 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 Turin Companies Registry on 3 November 1999 under no. PRA/91590/1999/CT00460; 
  
 AND 
  

	•	Dr. Rolando LORENZETTI, born in Florence, on 15.2.1953, acting herein in representation of “BIOSEARCH ITALIA S.p.A.” - a company with
registered offices and tax domicile in Milan at Viale Regina Giovanna 17 (Postal Code 20129), fully paid-up share capital of 12,160,500 euro, Tax and Milan Companies Registry no. 11922440158, entered in the National
Research Register (Anagrafe Nazionale Richerche) at no. 50181F67- by virtue of special power of attorney dated 5.4.2001, notarised by Dr. Alessio Michele Chiambretti, Notary in Saronno, under file no.
176181, a true copy/original of which has been issued to him by Mr. Claudio QUARTA, born in Lecce, on 10.1.1955, with an address for service in his official capacity at the registered offices of the aforesaid company, by
virtue of powers vested in the latter by resolution passed by the Board of Directors on 14.6.2000, and recorded in a public deed notarised on 5.4.2001, under file no. 176180, by Dr. Alessio Michele Chiambretti, Notary in
Saronno, member of the Notarial College of Saronno, a true extract of which is attached to the aforesaid special power of attorney; both the aforesaid deeds having been delivered to SANPAOLO IMI; 

  
 WHEREAS 
  
 a) pursuant to Article 7 of Ministerial Decree of 8 August 1997 (containing “New procedures for the award of project grants to be drawn
from the Special Fund for Applied Research”), “BIOSEARCH ITALIA S.p.A.” with registered offices and tax domicile in Milan (hereinafter also referred to as the “Beneficiary”), submitted, under the national
programme for cancer research, to the Ministry of Universities, and Scientific and Technological Research (MURST), a professional training and research project, pertaining to Theme “9” (Project no. 7918), entitled: “Setting
up of experimental procedures and screening methods for the development of new drugs”; 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 b) MURST has approved funding, in the manner, to the extent and at the terms and conditions contained in decree no.
748/Ric. dated 20.12.99 – published in the Official Gazette, general series, no. 10, dated 14.1.2000 – a copy of which is attached hereto as Exhibit “A” – for the project, made up of a research project and a training
project, both of which are to be implemented in accordance with the procedures, timetables, work progress phases and cost estimates, established in detail by mutual agreement between the parties; 
  
 c) the aforesaid decree provides that the duration of the project (established at 36
months for “research” and at 30 months for “training”) may be extended by 12 months to make up of any delays in implementing the related activities, and that only costs incurred following 23.1.1999 may be covered by the
contribution; in accordance with the above and with the understandings reached between the parties, the commencement and termination dates of the project have been established respectively at 1.2.2000 and at 31.1.2004 for
“research” and at 1.8.2000 and 31.1.2004 for “training”; 
  
 d) with regard to the venues at which the research is to be carried out, a distinction must be made between Ineligible Areas and Eligible Areas, the latter term meaning and including the Italian territories mentioned in Article 92(3)(a) and
(c) of the EC Treaty, as indicated in the list in force at the date of submission of the application for funding; 
  
 e) the European Union may contribute towards the funding provided hereunder for activities to be undertaken in the Eligible Areas falling under Objective 1, through the
European Regional Development Fund (ERDF) in accordance with the Operating Programmes in force from time to time; 
  
 f) pursuant to Article 6(6) of Decree Law no. 32 of 8 February 1995, converted into Law no. 104 of 7 April 1995, the receivables deriving from funding provided pursuant
to Article 2(2) of Law no. 46 of 17 February 1982 as amended must be secured by a general lien (see Article 10 below); 
  
 f-bis) pursuant to Article 12 of Ministerial Decree of 8 August 1997, the applicant may, against presentation of suitable performance bonds and/or insurance policies,
request an advance of 20% of the overall funding provided by way of contribution towards expenses (see Article 4-bis below); 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 g) the decree mentioned in Recital b above, sets forth the funds covering the expenses pertaining to the measures
implemented pursuant to the decree in question; 
  
 h) in respect of this
agreement, Sanpaolo IMI S.p.A. (hereinafter referred to as the “Bank”) acts on behalf and in the interest of the Italian Government solely in the Bank’s capacity as a Bank authorised for the management of research grants awarded by
the “Ministry”; 
  
 i) the relationship between the parties hereto shall
be governed by the regulations applicable to the Applied Research Fund and, more especially, by the MURST Decree of 8.8.1997 (published in supplement no. 232 to the Official Gazette no. 270 of 19.11.1997), express reference to which is here made,
and of which the parties hereby expressly declare that they are aware. 
  
 NOW THEREFORE 
  
 As an integral and material part of this
agreement, the parties agree and stipulate as follows: 
  
 ARTICLE 1 
  
 LEGAL SPECIFICATIONS

  
 The parties hereto approve the foregoing recitals and
stipulate that the funding shall be further governed, where applicable, by the terms and conditions contained in the “Legal Specifications” attached hereto as Exhibit “B” which are an integral and material part hereof, it
being understood that the parties hereto are fully aware of the contents of the said “Legal Specifications”, having specifically approved each and every clause thereof. 
  
 ARTICLE 2 
  
 AMOUNT OF THE FUNDING 
  
 The Bank hereby grants “BIOSEARCH ITALIA S.p.A.”, with registered offices and tax domicile in Milan, funding by way of the opening
of a credit line on the Special Fund for Applied Research, up to the maximum amount, in terms of principal, of 3,859,320,000 Italian Lire (three billion eight hundred and fifty-nine million three hundred and twenty thousand), as a
contribution towards expenses, of which, 3,359,320,000 Italian Lire is for research and 500,000,000 Italian Lire is for training. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 The aforesaid funding shall be made available in accordance with the provisions of Article 4 below. 
  
 ARTICLE 3 
  
 DOCUMENTS TO BE SUBMITTED 
  
 The Beneficiary undertakes: 
  
 a) to draw up – or to show that it has drawn up – an [*] on the research project, indicating the [*], scheduled to take place by [*] (or at the very latest
within [*] thereafter, in the case of unforeseeable delays), all the above, in accordance with the provisions contained in Recital b hereto; 
  
 b) to draw up – or to show that it has drawn up – an [*] on the [*] phase of the training project by [*] (or at the very latest within [*] thereafter, in the
case of unforeseeable delays), all the above, in accordance with the provisions contained in Recital b hereto; 
  
 c) to complete the research project mentioned in Recital b hereto by [*] at the very latest (inclusive of any extension of the scheduled duration of the research,
for a period of up to 12 months, to accommodate unforeseeable delays); 
  
 d) to
complete the training project mentioned in Recital b hereto by [*] at the very latest (inclusive of any extension of the scheduled duration of the training project, for a period of up to 12 months, to accommodate unforeseeable delays).

  
 The Bank shall refer any and all breaches of the obligations
assumed under subparagraphs a), b), c) and d) above to MURST for appropriate action. 
  
 The Beneficiary further undertakes: 
  
 e) to
provide the Bank, within [*] from the date hereof, and in the form required by the Bank, documentary evidence showing that the Beneficiary has lawfully entered into this agreement and that the Beneficiary is in no way hindered from enjoying any of
its corporate rights, as at a date following the stipulation hereof; 
  
 f) to
provide the Bank with any and all further technical, legal and administrative documents that the Bank may request or require; 
  
 g) to provide evidence showing that it has acquired full insurance coverage, especially against accidents, for all trainees other than the Beneficiary’s employees,
for the entire duration of the project; 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 h) to submit to the Bank, within [*] from the date of the [*] of the research project (and in any case, within [*]
following the [*] for such event, even in the case where the related research activities are not yet completed), or within [*] from the date hereof, a [*] on the [*] and the [*], both of which are to be prepared and drafted in accordance with the
forms and procedures set forth in the agreements mentioned in Recital b hereto; 
  
 i) to submit to the Bank, within [*] from the date of completion of the [*] phase of the training project (and in any case, within [*] following the final deadline for such completion, even in the case where the [*] phase of the training
project is not yet concluded), or within [*] from the date hereof, a [*] on the [*] and the [*], both of which are to be prepared and drafted in accordance with the forms and procedures set forth in the agreements mentioned in Recital b
hereto; 
  
 l) to provide the Bank, within [*] from the end of each [*] period
following the period of reference of the [*], the [*] regarding the activities undertaken in connection with both the research and the training aspects of the project, together with the [*], all of which must be prepared and drafted in accordance
with the forms and procedures set forth in the agreements mentioned in Recital b hereto; 
  
 m) to provide evidence – within [*] following the scheduled date of completion of the research project – that the project has in fact been completed, providing the Bank with a [*] on the [*] as well as on
the [*], together with a [*] for the [*], all of which must be prepared and drafted in accordance with the forms and procedures set forth in the agreements mentioned in Recital b hereto; 
  
 n) to provide evidence – within [*] following the [*] of the training project –
that the project has in fact been completed, providing the Bank with a [*] on the [*] as well as the [*], together with a [*] for the [*], all of which must be prepared and drafted in accordance with the forms and procedures set forth in the
agreements mentioned in Recital b hereto; 
  
 o) to authorise – even
on behalf of parties involved in partnerships with the Beneficiary, such as shareholders, partners in consortia, other group undertakings, subsidiary undertakings – checks of the proper use of national and EU resources, both through the
controls and inspections mentioned in Article III of the Specifications, and through a 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 specific, separate accounting of the costs sustained for the project – in accordance with the agreements mentioned
in Recital b hereto – and in particular, of the costs sustained in the Eligible Areas mentioned in Recital e hereto 
  
 p) to ensure that all the aforesaid documents are maintained available on file for at least [*] following the date of the last payment received under the funding granted
through this agreement; 
  
 q) to give the Bank [*] notice of any and all changes
in the powers mentioned in the preamble hereto, especially with regard to the powers to sign the compulsory declarations mentioned in Article 4 below; 
  
 r) to give the Bank [*] notice of any and all substantive changes in the Beneficiary’s management layout (especially, for instance, changes in the make-up of its
Board of Directors, replacement of the Sole Director) and to provide the Bank, in a [*], with the updated documents required under applicable Anti-Mafia regulations. In the case where the Beneficiary is a consortium, the same shall give the Bank [*]
notice of any and all substantive changes in the management layout of each of the consortium members holding more than a 10% participating interest in the consortium, and shall provide the Bank, in a [*], with the updated documents required under
applicable Anti-Mafia regulations. 
  
 s) to give the Bank immediate notice of any
and all general meeting resolutions entailing changes in the Beneficiary’s corporate layout (for instance, mergers and acquisitions, voluntary winding-up). 
  

ARTICLE 4 
  
 PROCEDURES AND CONDITIONS FOR THE DISBURSEMENT OF 
  
 FUNDING 
  
 No funds granted under this agreement may be disbursed until the obligations arising under Article 3(e), (f), (g), (h) and/or (i) above, have been fully performed. Funding shall be released gradually
consistent with the progress achieved in the completion of the research and training projects, and against presentation of the documents justifying refundable costs, mentioned in Article 3(l) above, on the basis of the percentages indicated
in the MURST decree mentioned in Recital b hereto. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 In particular, with regard to both projects, the first [*] shall take place upon [*] – to be
selected by [*] – as well as by [*]. Any and all findings by [*] that contradict project data and targets, shall be reported to MURST which may decide [*] in Article 13 below, or, only in the case where the unsatisfactory performance
witnessed in the first progress report, is not imputable to the Beneficiary, to [*] in Article 12 below. 
  
 Tranches of funding following the first release of funds shall be made available to the Beneficiary following [*] as well as by the [*], of [*]; in the
case of negative assessments, the procedure set forth in the preceding paragraph shall apply. 
  
 The release of funding shall also be subject to the conditions precedent set forth in subparagraphs a, b and c below, except for the [*], that shall be subject only to the conditions precedent
contained in subparagraphs a and b below. 
  
 a) The Beneficiary
shall maintain its full legal capacities throughout the duration of the agreement; should the Beneficiary be subjected to creditor protection proceedings, MURST shall decide whether to interrupt, revoke or continue the funding. 
  
 b) No sums are outstanding even with regard to a single payment due, for any reason
whatsoever, under this agreement or even other agreements stipulated with the Beneficiary pursuant to Law no. 46/82 as amended and Law no. 346/88; should the Beneficiary be found to be in arrears, MURST shall decide whether to interrupt, revoke or
continue the funding. 
  
 c) In terms of its economic and financial situation, the
Beneficiary shall maintain a ratio of less than [*]% between [*] (as per the Beneficiary’s last official financial statements). In the case where this threshold is exceeded, the funds released (except for the [*]) must be secured by a
performance bond (with regard to which, see Article 11 below). 
  
 By express agreement between the parties, and regardless of the Bank’s declaration of its intention to avail of the termination clause, the occurrence of any event that could give rise to termination, shall entitle the Bank to
immediately suspend the release of funding, by giving written notice thereof to the Beneficiary. 
  
 It is, however, expressly understood that should, after having released tranches of funding as mentioned above, the Bank find that the amounts released
exceed the percentage limits indicated in the cited MURST decree, or that the amounts released 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 pertain, in all or in part, to costs found to be incongruous, irrelevant or in any case, non-refundable under the terms
of this agreement, the Bank shall be entitled to suitably adjust any and all residual tranches of funding not yet released. In the case where there are no residual tranches of funding not yet released or where the latter are insufficient to cover
the excess funding released, the Beneficiary shall be bound to refund to the Bank in a single payment and within 30 days from receiving the Bank’s request to such effect, the excess funding released, increased, in both cases, by six month
interest payments as from the date of the release of the excess funds, at the official reference rate in force from time to time. 
  
 By express agreement between the parties, any and all funding shall be released subject to the actual availability of assigned financial resources.
Neither MURST nor the Bank may therefore be held liable to make any payments whatsoever in respect of delays in the release of funding, arising from a lack of financial resources. 
  
 Upon receipt of each tranche of funding, the Beneficiary shall sign a specific declaration of obligation, in the form
indicated by the Bank, and shall stipulate, within [*] from the Bank’s request to such effect, the final declaration, in the form established by the Bank. 
  

Failure to comply with the obligations arising under this Article, shall be construed as entitling the Bank to deem this agreement terminated by right.

  
 ARTICLE 4-bis 
  
 PROCEDURES FOR APPLICATIONS FOR ADVANCES 
  
 The Beneficiary may request an advance amounting to up to 20% of the amount
mentioned in Article 2 above, to be secured by a performance bond or insurance policy. 
  
 It remains expressly understood that should the Beneficiary exercise this option, portions of the tranches of funding to be released over the duration of the agreement, shall be used to cover the funding released in
advance. 
  
 In the case where MURST interrupts the funding
pursuant to Article 4 or Article 5 above, the amount of the funding earmarked to cover refundable costs shall be used to cover the advance funding provided; should such amount be insufficient to cover the said advance, the rest and
residue of the advance must be refunded, increased by interest 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 as from the date of release of the advance funding up to the date of final repayment thereof, at the official interest
rate of reference, in force from time to time during the aforesaid period. 
  
 By express agreement between the parties, in the case of revocation of the funding by MURST or the termination of this agreement, the amount released by way of advance must repaid, increased by interest as from the
date of the release of the advance up to the date of the repayment of the same, at the interest rate established by Decree of the Ministry of the Treasury and applicable as at the date hereof (six month rate of 1%), or at the legal interest rate
applicable at the time of revocation or termination, whichever is the greater. 
  
 ARTICLE 5 
  
 SUSPENSION
OR INTERRUPTION OF THE PROJECT 
  
 Should the Beneficiary
decide to abandon the project covered under the funding granted by virtue hereof, the Beneficiary shall give [*] notice thereof to the Bank, providing the reasons underlying such decision. The Bank shall suspend the release of funding and give
notice thereof to MURST that shall decide whether to revoke the funding, entailing the consequences set forth in Article 13 below, or, only in the case where the decision to abandon the project is based on reasons that cannot be imputed to
the Beneficiary, to [*] set forth in Article 12 below. 
  
 The Beneficiary may independently make changes to the economic layout and timetable of the project in terms of the disbursement of the funding over the years of the project, as well as over specific territories or, in the case of the
“research” portion, with regard to the type of activity (Industrial Research/Pre-competitive Development), provided that such changes do not alter the original profile of the research or training activities in question. 
  
 In all other cases, on the other hand, [*] and [*] must be notified by
registered letter with acknowledgement of receipt, about any and all [*]. The Bank shall then forward to MURST a report regarding the [*]. MURST shall [*] of the said [*], to the Beneficiary as well as to the Bank that shall then implement the terms
of the notice. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 It remains understood that should MURST [*], MURST may decide to revoke the funding, entailing the
consequences set forth in Article 13 below. 
  
 It remains
furthermore understood that, with regard to the training programme, reductions in the training hours included under the programme as completed up to the end of the period of reference of the [*], or of the entire project, in excess of [*]% of the
training hours indicated in the estimate, or absenteeism of individual trainees in excess of [*]% of the training hours included in the estimate of the programme for the period of reference of the [*], or of the entire project, shall entail [*] and
the [*] aimed at verifying that the Beneficiary cannot be held responsible for such reductions or absenteeism and that therefore the same must be accepted. In the case of negative findings, the situation shall be referred to MURST for appropriate
action. 
  
 In the case where trainees leave the programme as a
result of illness or other reasons not imputable to the Beneficiary, the costs sustained in respect of such trainees shall be covered up to the time of their departure from the programme. 
  
 ARTICLE 6 
  
 REPAYMENT 
  
 Without prejudice to the provisions of Article 13 below pertaining to the revocation of the funding or termination of the agreement prior to the
signing of the final declaration, pursuant to Law no. 675 of 12 August 1977 that set up this type of funding, the Beneficiary is not bound, in principle, to repay the amounts received by way of the funding granted hereunder. 
  
 Failure to make payment of any amount whatsoever due by virtue of this
agreement, shall entitle the Bank to terminate the funding agreement by right. 
  
 The nominal annual interest rate on arrears, payable pursuant to the provisions of Article VI of the Specifications, and calculated for the actual number of days/actual days, shall be the marginal lending
facility rate in force from time to time during the period of arrears, as established by the European Central Bank, and published on the Reuters network at page ECB01 (zero one) or in the “Il Sole 24 Ore” newspaper, increased by three
percentage points. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 ARTICLE 7 
  

PAYMENT PROCEDURES 
  
 By mutual agreement between the parties hereto, any and all payments due to the Bank under this agreement shall be made by the National Inter-bank Network
([*]). 
  
 ARTICLE 8 
  
 NON-CUMULATIVENESS 
  
 The Beneficiary represents and warrants that it has not been granted any
other public, national or international funding with regard to the project mentioned in Recital a hereto, and undertakes to inform the Bank of any and all further applications for and obtainments of such grants, so as to allow the competent
bodies to take appropriate action in such regard. 
  
 In the case
of false information or failure to inform the Bank as required above, the Bank reserves the right to deem this agreement terminated by right, entailing the consequences mentioned in Article 13 below. 
  
 ARTICLE 9 
  
 USE OF THE RESULTS 
  
 With regard to the goals of the “Fund” and in respect of any collaborative relationships or partnerships, howsoever arising between the
Beneficiary and overseas corporations, it remains expressly understood that: 
  

	•	up to the date of signing of the final declaration, the Beneficiary undertakes to refrain from transferring the results and know-how derived from the funded research project, in any
form whatsoever, in all or in part, to overseas corporations or undertakings controlled by overseas corporate groups (including those that are shareholders in the Beneficiary), except against receipt of due consideration for the same;

  

	•	the Beneficiary undertakes to develop industrial applications of the results of the research project covered hereunder, prioritising for such purpose, facilities located within
Italy. 

  
 By express agreement between the parties,
therefore, in the case of the Beneficiary’s failure to fulfil the foregoing obligations in whole or in part, the Bank 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 shall be entitled to deem this agreement terminated by right, entailing the consequences mentioned in Article 13
below, by giving [*] thereof to the Beneficiary. 
  
 ARTICLE 10

  
 SECURITY: LIEN 
  
 Without prejudice to prior rights of pre-emption or preference enjoyed by
third parties, the receivables arising from the release of the funding covered hereunder shall be secured by a general lien that shall prevail over any and all rights of pre-emption or preference, except for liens covering court costs and the
preferences mentioned in Article 2751-bis of the Civil Code. 
  
 ARTICLE 11 
  
 SECURITY: PERFORMANCE BOND/
INSURANCE POLICY COVERING 
  
 THE RELEASED FUNDING

  
 By express agreement between the parties, except with
regard to the last tranche of funding, should the assessment mentioned in subparagraph c of Article 4 above, carried out prior to the release of each individual tranche of funding, result in negative findings, the tranche to be
released must be secured by a performance bond issued by a credit institution approved by the Bank. The performance bonds issued in respect of individual tranches must remain valid and binding, up to the signing of the final declaration, failing
which the Bank reserves the right to deem this agreement terminated by right, entailing the consequences mentioned in Article 13 below. 
  
 Failure to present such guarantee within [*] from the Bank’s request to such effect, shall entail suspension of the funding up to final assessment of
the completion of the project, with regard to both the research and training aspects – without prejudice to the Beneficiary’s duty to fulfil all the obligations assumed hereunder with regard to the funding already released – it being
understood that the residual funding shall be released to coincide with the signing of the final declaration, in accordance with the provisions of Article 4 above, and after ascertaining that the requirements set forth in Article
4(4)(a) and (b) above, have been fully met. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 ARTICLE 12 
  

PART PAYMENT OF THE CONTRIBUTION 
  
 In the case of interruption of the funding by MURST, pursuant to Articles 4 and 5 above, the Bank, upon receiving MURST’s authorisation
in such regard, shall release the contribution due – in function of the costs deemed refundable under this agreement – and the parties shall at the same time, proceed with the signing of the final declaration mentioned in Article 4
above. 
  
 In the case where the Beneficiary has received an
advance, the procedure set forth in Article 4-bis above, shall apply. 
  
 ARTICLE 13 
  
 CONSEQUENCES OF THE TERMINATION OF THE AGREEMENT 
  
 The termination of the agreement or the revocation of funding shall entail an obligation binding on the Beneficiary to repay the Bank the amounts released, together with expenses and interest – as from the dates of the release of
individual tranches of funding up to the date of repayment – to be determined as indicated in the following paragraph, as well as any interest on arrears that may be due. 
  
 Interest shall be payable on the funds released either at the rate established by Decree of the Ministry of the Treasury,
applicable as at the date hereof (six month rate of 1%) or at the statutory interest rate applicable at the time of termination or revocation, whichever is the greater. In the case of termination for the reason contemplated in subparagraph a
of Article VIII of the attached Specifications, and without prejudice to the right to bring legal action, interest shall, in any event, be calculated as from the date of the release of the funds, either at the statutory interest rate in
force at the time of termination hereof, or at the rate of interest on arrears established in Article 6 above, whichever is the greater. 
  
 In any case, the failure to pay the amount owing, in accordance with Article VI of the Specifications, shall cause that the date, on which the interest for delayed
payment accrues, shall be established as provided by the Article 6 above. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 ARTICLE 14 
  

EXPENSES 
  
 Any and all expenses related, inherent or consequent to this agreement, and in general any and all other expenses or charges, including taxes, that
SANPAOLO IMI may have to sustain at present or in the future, with regard to this agreement or the performance and termination hereof, shall be borne solely by the Beneficiary that undertakes to hold the Bank harmless and exempt from liability in
such regard, it being expressly understood between the parties that non-compliance with such obligation shall entitle the Bank to terminate this agreement by right. 
  
 This agreement and any and all measures, deeds and formalities related to the performance and termination hereof, shall be
subject to the tax regime imposed under Presidential Decree no. 601 of 29.9.1973. 
  
 ARTICLE 15 
  
 ADDRESS
FOR SERVICE 
  
 The parties hereto elect the following as
their respective addresses for service: 
  

	•	SANPAOLO IMI S.p.A., in Rome, at its secondary headquarters at Viale dell’Arte 25; 

  

	•	“BIOSEARCH ITALIA S.p.A.” in Milan, at its registered offices at Viale Regina Giovanna 17 (Post Code 20129); 

  
 And all the parties, by default, at the town hall of their respective cities of residence or
incorporation, pursuant to Article 141 of the Code of Civil Procedure. 
  
 Read,
approved and signed, 
  
 In Rome, on 13 April 2001. 
  

					
	 SANPAOLO IMI S.P.A.
	 	 	 	 THE BENEFICIARY

			
	 /s/ Giuseppe Colona
	 	 	 	 /s/ Rolando Lorenzetti

	
	 	 	 	

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 Pursuant to Article 1341(2) of the Civil Code, the Beneficiary hereby declares that it specifically approves the
provisions of Articles 1, 2, 3, 4, 4-bis, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14 of this agreement. 
  

					
	 SANPAOLO IMI S.P.A.
	 	 	 	 THE BENEFICIARY

			
	 /s/ Giuseppe Colona
	 	 	 	 /s/ Rolando Lorenzetti

	
	 	 	 	

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 Exhibit A 
  

MINISTRY OF UNIVERSITY AFFAIRS AND 
 SCIENTIFIC AND TECHNOLOGICAL RESEARCH 
  
 DECREE of 20 December 1999.

  
 Acceptance for financing of research and training projects
involving the National Program of Research and Training for Technology in Oncology, as per Administrative Decree no. 748 Ric. of 20 December 1999. 
  
 THE DIRECTOR 
 OF
THE DEPARTMENT FOR THE DEVELOPMENT AND REINFORCEMENT OF RESEARCH ACTIVITIES 
  
 In light of Law no. 168 of 9 May 1989: “Establishment of the Ministry of
University Affairs and Scientific and Technological Research”; 
  
 In light of Law no. 46 of 17 February 1982: “Initiatives for sectors of the economy of national importance”; 
  
 In light of art. 15, paragraph 3, of Law no. 67 of 11 March 1988 on the professional training of researchers and research technicians; 
  
 In light of Legislative Decree no. 29 of 3 February 1993, plus subsequent
modifications and additions; 
  
 In light of Law no. 20 of 14
January of 1994 
  
 In light of Ministerial Decree no. 254 of 23
February 1995 regarding the composition and the operating procedures of the scientific technical committee referred to under art. 7 of Law no. 46/1982, plus subsequent modifications; 
  
 In light of Decree no. 512-Ric of 26 May 1998, registered with the State Audit Court on 11 June 1998, in which the Ministry
of University Affairs and Scientific and Technological Research approved the national program of training and research for technology in oncology, for maximum funding of 80 billion Lire; 
  
 In light of Ministerial Decree no. 954 of 8 August 1997, published in ordinary supplement no. 232 of the Official
Gazette, issue no. 270 of 19 November 1997, “New procedures for the granting of the subsidies contemplated under initiatives to be financed from the Special Fund for Applied Research”; 
  
 In light, in particular, of art. 7 of the aforementioned decree, which
regulates the national programs and the research contracts; 
  
 In
light of the Ministerial Decree of 22 July 1998, published in the Official Gazette of 6 August 1998, issue no. 182, containing “an invitation for the presentation of projects regarding the themes of the National Program of Research and
Training for Technology in Oncology”; 
  
 In light of the
applications presented under the provisions of art. 7 of Ministerial Decree no. 954 of 8 August 1997, plus the related evaluation outcomes; 
  
 In light of the note of the Minister of University Affairs and Scientific and Technological Research “Distinctions between management functions and
functions of political administrative guidance” of 6 August 1999, no. 306-Segr.; 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 Taking into account the opinions expressed by the National Scientific Committee in the meetings of 27
July, 9 November and 15 December 1999; 
  
 Considering that, for
all the parties that have presented projects accepted for financing, there exists, or is currently being acquired, the certification referred to under Legislative Decree no. 490 of 8 August 1994, as supplemented by art. 15 of Law no. 135 of 23 May
1997, plus subsequent modifications and additions; 
  
 Decrees:

  
 Art. 1. 
  
 The projects of research and professional training presented by the following
parties, in the forms, to the extent and under the procedures indicated for each case in the respective forms included as annexes, which represent a full and integral part of the decree, are accepted for financing: 
  
 theme 1 – Antibiotics S.p.A. – Rodano (Milan); 
  
 theme 2 – Research Toxicology Centre S.p.A. – Pomezia +
Tecnofarmaci S.c.p.a. – Pomezia (Rome); 
  
 theme 3 –
Diesse diagnostica senese S.r.l. – Milan; 
  
 theme 4 –
CSRB – Consortium for the Development of Biomedical Research – Genoa; 
  
 theme 5 – Picker Italia Medical Systems S.p.a. – Vimercate (Milan); 
  
 theme 6 – Tecnofarmaci S.c.p.a. – Pomezia (Rome); 
  
 theme 7 – Tecnofarmaci S.c.p.a. – Pomezia (Rome); 
  
 theme 8 – CSRB – Consortium for the Development of Biomedical Research – Genoa; 
  
 theme 9 – CSRB – Consortium for the Development of Biomedical
Research – Genoa; 
  
 theme 10 – CSRB – Consortium
for the Development of Biomedical Research – Genoa – Gen Era S.p.a. – Milan; 
  
 theme 11 – Tecnofarmaci S.p.a. – Pomezia (Rome); 
  
 theme 12 – Tecnofarmaci S.p.a. – Pomezia (Rome) + CSRB – Consortium for the Development of Biomedical Research – Genoa; 
  
 theme 13 – Sigma Tau – Industrie Farmaceutiche Riunite S.p.a. – Rome; 
  
 theme 14 – Hitesys R & D & Ambiente S.p.a. – Aprilia
(Latina); 
  
 theme 15 – CSRB – Consortium for the
Development of Biomedical Research – Genoa – Olivetti sanità S.p.a. – Ivrea (Turin) + Sago S.p.a. – Florence; 
  
 theme 16 – Tecnofarmaci S.c.p.a. – Pomezia (Rome) 
  
 Art. 2 
  
 The duration of the research and training projects may be augmented by twelve months to compensate for any delays in the performance of the activities
contemplated under the contexts. 
  
 The date from which the costs
for the research activities are calculated, in accordance with the provisions of art. 4, paragraph 14, of the Ministerial Decree of 8 August 1997, must fall no later than the thirtieth day from the publication of the present decree, on pain of
losing the financing. 
  
 Training activities may begin on a date
following that set for the research activities. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 Under the provisions of art. 12 of the aforementioned Decree no. 954, the company is entitled to request
an advance on the payment, assuming that the advance is covered by a bank guarantee or an insurance policy, for an amount of up to 20% of the ministerial financing. 
  
 In the case of contracts made out to more than one party, liability is held jointly. 
  
 In the case of contracts signed with consortiums of representation, the
payments for the activities performed by the consortiums shall be made directly to the consortiums, based on the reports presented, without any obligation of invoicing, by the members of the consortium. 
  
 Art. 3. 
  
 Transfer of the title to the contract for the project “Improvement of diagnostic supports for images” (theme 6)
from Tecnofarmaci S.c.p.a. to Kenton S.r.l. is authorised. Authorisation is also given for transfer of the title to he contract for the project “Preparation of experimental procedure and methods of screening for the development of new
pharmaceuticals” (theme 9) from the CSRB – Consortium for the Development of Biomedical Research to Biosearch Italia S.p.A.. 
  
 Art. 4. 
  
 Authorisation is granted for transfers of the title to the contracts for the projects presented by Tecnofarmaci S.c.p.a. under themes 2, 3, 7, 11, 12 and
16 to consortiums of participation established among the parties, and already participating in the research activities, as indicated in the reports included as annexes, which represent a full and integral part of the present decree. 
  
 Art. 5. 
  
 The managing institute, under the provisions of the combined measure consisting of articles 7 and 4 of the aforementioned
Ministerial Decree no. 954 of 8 August 1997, shall ensure that all the necessary formalities have been carried out for the signing of the contracts referred to under the present decree, as well as for the management of these contracts. 

 
 Art. 6. 
  
 The resources needed for the initiatives referred to under art. 1 of the present decree are calculated at 78,901,860,000
Lire, of which 68,926,510,000 Lire are for research activities and 9,975,350,000 Lire are for training activities and shall be charged to the funds of the FSRA already allocated under Ministerial Decree no. 512-Ric of 26 May 1998, referred to in the
introductory points. 
  
 The present decree shall be published in
the Official Gazette of the Italian Republic. 
  
 Rome, 20
December 1999 
  
 The Director:
CRISCUOLI 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

 SUMMARY OF TERMS FOR CONTRACTING SUBJECT: BIOSEARCH Italia S.p.A. – Milan 
  
 Project no. 7198 – Theme 9 
  
 TITLE: “Preparation of experimental procedures and screening methods for the development
of new pharmaceuticals” 
  

					
	 DURATION:
	 	Research	 	3.0 years (36 months)
	 	 	Training	 	2.5 years (30 months)

  
 Costs calculated from: 23
January 1999, and no later than the thirtieth day from the date of publication of the present decree. 
  

					
	 APPROVED COST:
	 	Research	 	5 billion Lire
	 	 	Training	 	500 million Lire

  
 The grants were further subdivided
into categories of activity. 
  
 SUBSIDIES APPROVED: 
  

					
	 Research
	 	spending contribution up to:	 	3,359.32 million Lire
	 Training
	 	spending contribution up to:	 	500.00 million lire

  
 These subsidies, in accordance with
the maximum amounts indicated above, must be applied to the approved costs on the basis of certain percentages of intervention. 
  
 Conditions for the financing: satisfaction of the guarantees required during the background control phase by the managing institute, to be implemented before the
signing of the contract. 

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

			
	 Procedure of 8.8.1997
	  	Exhibit B
	 B+CS, EUREKA, TRAINING, NATIONAL RESEARCH PLAN (PNR)
	  	 

  
 LEGAL SPECIFICATIONS

  
 OF THE AGREEMENTS AND CONDITIONS THAT CONSTITUTE AN INTEGRAL PART OF
CONTRACTS FOR FUNDING IN THE FORM OF SUBSIDIZED LOANS AND/OR CONTRIBUTIONS TO EXPENSES, STIPULATED BY SANPAOLO IMI S.P.A. (the “BANK”), TO BE DRAWN FROM THE SPECIAL FUND FOR APPLIED RESEARCH 
  

					
	Patents	  	Article I	  	 In the case where the Beneficiary deems it necessary or useful to obtain industrial patents in Italy or overseas, deriving directly or indirectly from the
performance of the programme in question, the Beneficiary shall bear any and all expenses related thereto.

			
	Exemption of Liability	  	Article II	  	 The Beneficiary shall operate in complete autonomy and in keeping with applicable national and EU statutory provisions and regulations, assuming full
responsibility for the completion of the project; the Bank and MURST shall therefore remain unconnected with any relationship, howsoever arising, with third parties with regard to the performance of the project, and shall be totally exempt from
liability for any damage whatsoever arising directly or indirectly from project-related activities.

			
	Controls and Inspections	  	Article III	  	 Public Administrations, EU Bodies, as well as monitoring and oversight bodies appointed for the purpose, may undertake checks
and inspections aimed at verifying compliance with national and EU regulations, the conformity of existing documents to reported expenses, the proper use of EU and national resources, as well as the maintenance of specific separate books.

 
 Furthermore, the Bank may, through its representatives and at the
intervals and in the manner it deems fit, carry out technical, accounting and administrative checks, as well as inspections of any nature whatsoever, related to the project or to the industrialisation of the results thereof, it being obviously
understood, that in keeping with its statutory obligations, the Bank shall treat any and all information and technical data of which it may become aware either during the aforesaid appraisals, or as a result of disclosures made by the Beneficiary to
the Bank, with the confidentiality required in order to ensure proper protection of the Beneficiary’s interests.
  
 The Beneficiary shall furthermore be bound to provide the Bank with its financial statements and profit and loss accounts, featuring a breakdown of
individual items.
  
 Should the Beneficiary fail to comply
with the above obligations, or should the Beneficiary’s legal, administrative, technical or economic situation depart from that represented to the Bank at the time the funding was approved, the Bank reserves the right to terminate the funding
agreement by right, entailing the consequences set forth in the relevant contractual clauses.

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
	Payments and Charges	  	Article IV	  	 Any and all amounts howsoever due to the Bank, must be paid to the Bank net of any and all charges.
  
 Any and all expenses by way of taxes, duties and other encumbrances of
any nature or kind whatsoever and regardless of whether the same are direct or indirect, personal or in rem, present or future, that may be charged to the Bank at the time of the approval of the funding or thereafter, as well as any and all
increases in current taxes, shall be borne solely by the Beneficiary that, must, at all times, hold the Bank harmless and exempt from liability in such regard, providing the Bank, even in advance, with the monies due by way of taxes, without
prejudice to the Beneficiary’s right to take any and all action as it may deem fit, especially by way of contestation, it being understood that the Bank shall be entitled to consider itself totally unconnected with any and all such
action.

			
	Subrogation and Right of Recourse	  	Article V	  	 The contracting parties hereby waive their right to seek enforcement against the Bank, of any and all rights of subrogation and/or recourse they may enjoy in
respect of payments made under present and/or previous funding provided and/or secured by even only one of the said contracting parties, until full and final payment of any and all receivables due to the Bank (in terms of principal, interests,
expenses and any and all ancillary charges) under the present and/or previous funding agreements stipulated pursuant to Law no. 46/1982 (as amended) and Law no. 346/1988.

			
	Interest on Arrears	  	Article VI	  	 Any and all outstanding amounts due from the Beneficiary, shall, by full right, bear interest on arrears in favour of the Bank, at the agreed rate, such
interest being due by full right and therefore without the need for any notice or other prior warning whatsoever.

			
	Advance Withdrawals	  	Article VII	  	 The Beneficiary may request the advance withdrawal of all or part of the funding, provided that:
  
 a)      the
Beneficiary has properly fulfilled all its obligations under the agreement;
  
 b)      repayment will be made in cash.
  
 In the case of where a partial advance withdrawal is made, the Bank
reserves the right to determine whether the amount of the advance is to be imputed to the last tranches of the funding (keeping the [*] payments unchanged, but reducing the duration of the funding) or to be repaid through a reduction in the
[*] tranches (leaving the duration of the funding changed).
  
 Partial advance withdrawal of the funding shall not entail the right to reduce or restrict the guarantees provided; should, however, the Bank feel that it can accept such reductions or restrictions for any reason, the Bank shall,
[*], establish the terms and conditions thereof, without the need to serve notice thereof on any party whatsoever.

			
	Other Reasons for the Termination of the Agreement	  	Article VIII	  	 The Bank reserves the right to terminate the funding agreement by right, not only in the cases already expressly contemplated,
and in the event of any breach of the Beneficiary’s obligations, as well as in the cases contemplated under law, but also in the case of:
  
 a)      the issue, by the Beneficiary of false declarations, documents or other deeds;

 
 b)      failure by
the Beneficiary to present, even only one of the technical and accounting documents required under agreement, within the contractually established time limits, or in the forms prescribed, or the breach of the obligation to prepare and properly
maintain evidentiary documents of a technical or accounting nature;
  
 c)      the cancellation of other funding approved in favour of the Beneficiary pursuant to Law no. 46/82 as further extended and Law no. 346/88;

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
	 	  	 	  	  
 d)      filing by the Beneficiary or any parties standing surety in the favour of the Beneficiary, for temporary receivership, creditor protection or the transfer of assets to creditors;
  
 e)      filings for
the bankruptcy, compulsory or voluntary winding-up of the Beneficiary and/or any of the parties standing surety in its favour;
  
 f)      reduction in the general asset-based guarantees of the Beneficiary and/or any of the
parties standing surety in its favour;
  
 g)      closure or change in the Beneficiary’s core business;
  
 h)      transformation or merger of the Beneficiary into another company.

			
	Joint and Indivisible Nature of Contractual Obligations	  	Article IX	  	 All the obligations arising under the agreement shall be deemed to be assumed by the Beneficiary and any and all of its guarantors jointly and indivisibly, on
their own behalves and on the behalf of their heirs, successors and assigns.

			
	Beneficiary’s Obligations in the Case of Contestations	  	Article X	  	 By express agreement between the parties, no contestation raised by the Beneficiary or otherwise arising between the parties, may be construed as suspending the
Beneficiary’s obligation to refund, at the established due dates, the amounts due by way of interest on and amortisation of the funding released, or any other obligations whatsoever arising by virtue of the agreement.

			
	Jurisdiction and Venue	  	Article XI	  	 Jurisdiction over any and all disputes that may arise from the agreement shall lie solely with the Courts of Rome.

			
	National and EU Regulations	  	Article XII	  	 The Beneficiary shall be bound to comply with national and EU regulations pertaining to environmental impact and equal
opportunities at the workplace.
  
 For the entire duration of
the funding, the Beneficiary shall further be bound to [*] and [*].
  
 In the case where sanctions are imposed against the Beneficiary for non-compliance with the aforesaid obligations (for instance pursuant to article 36(3) of Law no. 300 dated May 20, 1970 and article 3(9) of Law no.
125 dated April 10, 1991) and such sanctions entail the revocation of the funding, the funding agreement shall be deemed terminated by right, entailing the consequences specified in the relevant contractual clause.

  

	
	Rome, 13 April 2001
	
	 Read, approved and signed

  

	
	
	 /s/ Rolando Lorenzetti

	

  

	
	SANPAOLO IMI S.P.A.
	
	 /s/ Giuseppe Colona

	

  
 Pursuant to Article 1341(2) of
the Civil Code, the Beneficiary hereby declares that it specifically approves the provisions of articles I, II, III, IV, V, VI, VII, VIII, IX, X, XI and XII of these Legal Specifications. 
  

	
	
	 /s/ Rolando Lorenzetti

	[*]	Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]